Streetwise Reports' Article Archives — July 2019 back to current month (37)
The designation, opinion and asset are discussed in a ROTH Capital Partners report.
Firm's Cannabis Flower Yield Surpasses Expectations (07/29/2019)
Also, the company begins growing a second strain.
Mylan Gets a Shot in the Arm with Pfizer Merger Deal (07/29/2019)
EpiPen manufacturer Mylan N.V. announced that the company will merge with Pfizer Inc.'s Upjohn Division, which holds Pfizer's off-patent branded and generic drugs, forming a new company.
Catasys: This Is Bigger Than You Think (07/26/2019)
Daniel Carlson of Tailwinds Research examines the "blockbuster" implications of a recent announcement about this company's OnTrak program.
The prognosis for online exchange operator eHealth Inc. looks positive as the company reported a 101% increase in Q2/19 revenues over the prior year period and raised full year 2019 revenue estimates by $50 million to $365–385 million, compared with previous guidance of $315–335 million for 2019.
Orthodontic and GP Dental medical device maker Align Technology announced a 24.6% increase in sales volume of its Invisalign products in its Q2/19 earnings report, but investors are not smiling much over China growth concerns as the shares of the company have fallen more than 25%.
Anixa Licenses Another Potential Blockbuster (07/24/2019)
Daniel Carlson of Tailwinds Research discusses a major collaboration with the Cleveland Clinic for his top pick stock of the year.
Edwards Lifesciences is trading higher after reporting higher than expected adjusted earnings for Q2/19. The company estimates that the FDA will approve its SAPIEN 3 valve and SAPIEN 3 Ultra system in Q3/19.
The company's most advanced assets are discussed in a Dawson James Securities report.
The immuno-oncology company's findings are reviewed in a ROTH Capital Partners report.
The specifics and benefits of the deal are discussed in an H.C. Wainwright & Co. report.
The company discussed both its Alzheimer's disease and ALS programs.
These assets complement the company's primary care clinics and telemedicine and electronic medical record functionality.
The two California-based companies will collaborate on specific related development activities.
Peter Epstein of Epstein Research checks into the most recent developments announced by this company, which include planting 130,000 hemp plantlets on 40 acres.
The FDA deemed the firm's submission for analgesic approval complete.
The study results and their meaning are reviewed in an H.C. Wainwright & Co. report.
The primary reason for the rating—upcoming trial results—is discussed in an Echelon Wealth Partners report.
This step moves the product further down the development track.
The product will be launched under its brand for the recreational market.
Seattle Genetics announced a 28.3% increase in net sales for its second quarter 2019 powered by ADCETRIS sales along with a promising pipeline.
A description of the asset and its potential are provided in a Dawson James report.
Its newly entered agreement offers potential for future growth in Canada.
Galapagos announced that Gilead Sciences has agreed to pay $3.95 billion for a 10-year partnership and licensing deal and will invest an additional $1.1 billion in newly issued shares of the company.
Technical analyst Clive Maund charts the stock of this company that has developed a device that uses a special light that visualizes cancer during minimally invasive surgery.
Illumina Inc. shares traded down more than 15% as the company reported lower preliminary Q2/19 revenues and updated its annual revenue guidance.
CVS Healthcare announced a $0.50/share quarterly dividend yesterday and got an added boost today as news spreads regarding easing of federal restrictions on pharmacy rebate plans.
A study description and expected data readouts this year are provided in a ROTH Capital Partners report.
The investment thesis on this immunotherapies developer is made in an H.C. Wainwright & Co. report.
The two firms involved plan to have the offering fully rolled out by Q3/19.
Sangamo Therapeutics and partner Pfizer reported positive results for phase 1/2 Alta study for hemophilia A at the International Society on Thrombosis and Hemostasis Congress in Melbourne, Australia.
The case is made in a ROTH Capital Partners report for investing in this U.S.-based pharma having multiple shots on goal.
Health Technology Company Recuperating Well (07/03/2019)
Technical analyst Clive Maund charts a medical technology firm and explains why he believes it is an interesting speculative play.
Amarin shares are spiking up today by more than 12% on greater than five times 50-day average volume after the company updated its annual revenue forecast and plans for Vascepa.
Bioasis Engages With the FDA: Here's What It Means (07/02/2019)
Daniel Carlson of Tailwinds Research examines the implications of correspondence with the regulatory agency as the company advances its lead candidate addressing brain cancer.
An H.C. Wainwright & Co. report presented the investment bank's reasons for its bullish view on this California-based biotech.
The terms of the financial transaction and the potential reasons for it are discussed in a BTIG report.
|"From a stock perspective, 2019 was a clear breakout year for DRRX."|